Entry39.8→Now39.75
Enrollment pause drives Xenon's steep selloff Open original source
XENE Xenon Pharmaceuticals Inc Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
02:03
Sep 20
Sep 20
XENE is an attractive M&A target for its epilepsy program.
The author believes Xenon Pharmaceuticals is undervalued given the potential $5.5 billion M&A valuation for its focal epilepsy program. The recent trial news may actually facilitate an acquisition if the company decides not to resume the trial. The primary risk is the uncertainty surrounding the trial's future and the company's strategic direction.
HIGH
18:31
Sep 18
Sep 18
XENE selling overdone, buy the dip
Buy Xenon Pharmaceuticals on the view that the recent selloff is overdone and the dislocation is an actionable long opportunity, with the author framing it as a repeat of a prior setup.
MED
16:26
Sep 18
Sep 18
Enrollment pause drives Xenon's steep selloff
Xenon voluntarily paused enrollment in clinical studies of azetukalner for major depressive disorder and bipolar depression after adverse events, driving its worst day since 2017 and overshadowing the regulatory filing for its lead drug candidate that had put it on the brink of its first commercial product; Wall Street is split on the impact.
MED
12:27
Sep 18
Sep 18
US pre-market movers show TXN raising its quarterly dividend.
US pre-market movers show TXN raising its quarterly dividend, ONON signing Kylian Mbappe away from Nike, NUE and STLD issuing light guidance, NFLX downgraded at Wells Fargo, and XENE plunging on paused patient enrollment in depression trials.
12:05
Sep 18
Sep 18
Zerohedge lists premarket movers including Alphabet leading the Magnificent 7 higher.
Zerohedge lists premarket movers including Alphabet leading the Magnificent 7 higher, Netflix dropping on a Wells Fargo downgrade, and Xenon tumbling after pausing depression drug trials.
16:08
Aug 26
Aug 26
Author compares street vs retail biotech top lists and notes RVMD approval with pricing.
Author compares street vs retail biotech top lists and notes RVMD approval with pricing expectations, but frames all names as observational research rather than personal positions.
LOW
13:23
Aug 21
Aug 21
Consensus biotech longs round-trip as regrossing starts
Degrossing used these crowded biotech longs as the ATM to fund short covering; with regrossing already starting, gross rebuild should push these names back up as flows round-trip.
MED
23:38
Aug 19
Aug 19
The author lists speculative biotech catalysts and best ideas by therapeutic area.
The author lists speculative biotech catalysts and best ideas by therapeutic area as research/watchlist content, not explicit current positions or forward calls.
23:36
Aug 19
Aug 19
Top biotech picks across various therapeutic areas
Author lists these biotech names as their best ideas across various therapeutic areas with the sector near all-time highs.
MED
13:05
Aug 17
Aug 17
Shares options positioning net conviction data.
Shares options positioning data showing net conviction based on fund holdings, no directional view.
MED
12:56
Aug 17
Aug 17
Reports heaviest selling across specialist funds
"Reports net conviction laggards with heaviest genuine selling across specialist funds in Q2 2026, no directional view."
MED
12:53
Aug 17
Aug 17
Reports widest ownership across specialist funds
"Reports widest Q2 2026 ownership across 95 specialist funds based on 13F filings, no directional view."
MED
12:50
Aug 17
Aug 17
Reports most reduced positions across funds
"Reports most reduced positions across specialist funds in Q2 2026 excluding M&A take-outs, no directional view."
MED
12:01
Aug 17
Aug 17
Reports Q2 net conviction from specialist funds
Reports Q2 net conviction chart based on 13F filings from specialist funds.
MED
11:58
Aug 17
Aug 17
Reports widest Q2 ownership among specialist funds
Reports the widest Q2 2026 ownership across 93 specialist funds based on 13F filings.
MED
11:53
Aug 17
Aug 17
Reports most reduced positions by specialist funds
Reports the most reduced positions by specialist funds in Q2 2026, excluding M&A takeouts.
MED
05:59
Jul 27
Jul 27
Author highlights Affinity's golden run in biotech and their top 5 FBRX holding post-APGE.
Author highlights Affinity's golden run in biotech and their top 5 FBRX holding post-APGE acquisition, celebrating broad sector gains without explicit forward calls on most names.
LOW
00:07
Jul 27
Jul 27
Buy XENE as a second-tier derisked/M&A candidate.
Buy XENE as a second-tier derisked/M&A candidate; speaker also names it as favorite in the neuro disease space, suggesting pipeline conviction alongside M&A optionality.
MED
13:13
Jun 21
Jun 21
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A.
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A timing framework shows this is the window where acquirers with pre-committed capital execute; sector M&A wave across radiopharmaceuticals, MASH, IBD, and obesity validates the pattern is active.
MED
00:55
Jun 21
Jun 21
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom.
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
LOW
15:09
May 29
May 29
The author highlights Chris Staral's past holdings and return under Triple Helix.
The author highlights Chris Staral's past holdings and return under Triple Helix, but this is a historical research summary and watchlist, not an active position or forward call.
LOW
About XENE Investor Commentary
Across the available history and selected sources, Buzzberg tracks XENE (Xenon Pharmaceuticals Inc) across 5 sources: 4 bullish vs 1 bearish calls from 5 authors. Historical directional balance: 14% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 21 total trade ideas tracked. Past 7 days, before deduplication: 2 bullish, 1 bearish, 2 other directions. Latest voices: u/SimmondsW7, seedy19tron, Romaine Bostick.